Paroxysmal hemicrania: a prospective clinical study of 31 cases.

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Abstract Text:

Elisabetta Cittadini,Manjit S Matharu,Peter J Goadsby,Elisabetta Cittadini,Manjit S Matharu,Peter J Goadsby,

Paroxysmal hemicrania is a rare syndrome characterized by repeated attacks of strictly unilateral, severe, short-lasting pain occurring with cranial autonomic features. The hallmarks of this syndrome are the relatively short attacks and the exquisite response to indometacin. We describe the phenotype of this condition in a series of 31 patients. The mean duration of attack was 17 min. The mean attack frequency was 11. The distribution of the pain was orbital and temporal in 77% of the patients, retro-orbital in 61%, frontal in 55%, occipital in 42%; although pain was also reported in the vertex, second division of trigeminal nerve, neck, nose, jaw, parietal region, ear, teeth, eyebrow, shoulder (ipsilateral and bilateral), arm and third division of trigeminal nerve. Of the cohort, 87% had lacrimation, 68% had conjunctival injection, 58% rhinorrhoea, 54% nasal congestion, ptosis and facial flushing. Other cranial autonomic features include eyelid oedema, forehead/facial sweating, sense of aural fullness and periaural swelling, miosis, mydriasis and swelling of the cheek. The majority of the patients (80%) were agitated or restless, or both, with the pain and 26% were aggressive. All patients had positive placebo control indometacin test (100-200 mg intramuscularly), or a positive oral indometacin trial or both. We suggest the International Headache Society criteria be revised to remove specification of attack site, and to include the full range of cranial autonomic features. Currently, the sine qua non for paroxysmal hemicrania is a response to indometacin. Since there is no reliable clinical marker of that response we recommend an indometacin test, either orally or by injection for any patient with lateralized discrete attacks of head pain with associated cranial autonomic symptoms.

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Publishing Authors By Initials

E Cittadini,MS Matharu,PJ Goadsby,E Cittadini,MS Matharu,PJ Goadsby,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Brain : a journal of neurology

VOLUME: 131

Page Numbers: 1142-55

Journal Abbreviation:

ISSN: 1460-2156

DAY: 5

MONTH: 02

YEAR: 2008

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372537

Paroxysmal hemicrania: a prospective clinical study of 31 cases. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Paroxysmal hemicrania: a prospective clinical study of 31 cases. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Paroxysmal hemicrania: a prospective clinical study of 31 cases.

AFFILIATION:

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Brain

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Paroxysmal hemicrania: a prospective clinical study of 31 cases Related Publications

• Abnormal blink reflex studies in a patient with supraorbital neuralgia.
• Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat.
• Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
• Benign cough headache.
• Bilateral paroxysmal hemicrania or bilateral paroxysmal cephalalgia, another novel indomethacin-responsive primary headache syndrome?
• Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?
• Chronic headache and pituitary tumors.
• Cluster headache: new perspectives.
• Diffusion- and perfusion-weighted MR imaging in persistent migrainous visual disturbances.
• Dopamine and migraine: biology and clinical implications.
• Familial SUNCT.
• How do the currently used prophylactic agents work in migraine?
• Is a central action of acute antimigraine drugs essential?
• Migraine management: contrasting patient preferences with current clinical end points: introduction.
• Neuropeptides and migraine--a useful biological marker?
• Neuropeptides in migraine and cluster headache.
• Neurostimulation in primary headache syndromes.
• Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine.
• Octreotide is not effective in the acute treatment of migraine.
• Paroxysmal hemicrania in a family.
• Paroxysmal hemicrania: a prospective clinical study of 31 cases.
• Placebo response in cluster headache trials: a review.
• Rizatriptan in acute treatment of migraine: update on new comparative data.
• SUNCT syndrome in the elderly.
• The mode of action of sumatriptan is vascular? A debate.
• The paroxysmal hemicrania-tic syndrome.
• Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
• Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias.
• Update on the prophylaxis of migraine.
• What is the physiological role of the trigeminovascular system?